ActoGeniX, a development stage biopharmaceutical company, announced that the United States´ Food and Drug Administration (FDA) has approved the Company´s Investigational New Drug (IND) application for AG013, a novel therapeutic product for the treatment of oral mucositis in cancer patients. This IND application approval allows ActoGeniX to initiate a phase 1B clinical trial with AG013, which will now become the second clinical development program in ActoGeniX´s portfolio. Continue reading ...
Sunday, May 17, 2009
Subscribe to:
Posts (Atom)
